Individuals with a genetic predisposition to Alzheimer’s disease show altered blood levels indicating damaged neuronal contacts as early as 11 years before the expected onset of dementia symptoms. This is evident in the levels of the protein “beta-synuclein”. An international team report these findings in the journal “Alzheimer’s & Dementia”. The biomarker studied here could potentially help to detect neurodegeneration at an early stage.

The “Digital Integration and Innovation in Surgery” project aims to promote the transfer of new findings and research results into practice. The School of Informatics at Reutlingen University will work together with Furtwangen University, BioMedTech e.V., University Hospital Tübingen and other stakeholders to examine how intelligent digital assistance systems can contribute to improved patient care during surgical procedures.

Baden-Württemberg AI Alliance - 08/04/2025

Achieving widespread use of AI

Artificial intelligence presents both opportunities and risks. The Baden-Württemberg AI Alliance is dedicated to fostering collaboration among AI stakeholders to ensure that AI solutions deliver tangible benefits to citizens and businesses across the state. The alliance will also place greater emphasis on advancing AI applications within the healthcare sector.

Germany's most important award for young scientists honors the development of immunotherapies against malignant brain tumors.

The weight of expectant mothers could play a role in the development of acute lymphoblastic leukemia (ALL) in daughters – but not in sons. This has been shown by researchers at the German Cancer Research Center (DKFZ).

The Max Planck Society and the Dieter Schwarz Foundation (DSS) have embarked on a groundbreaking initiative. On March 13, 2025, they signed an agreement through which the foundation will support an innovative approach by the Max Planck Institute for Medical Research in Heidelberg to translate basic research findings into practical applications. As part of this endeavour, two new departments of the institute will be established in Heilbronn.

Scientists at the Max Planck Institute for Intelligent Systems, the University of Tübingen and the University of Stuttgart under the Bionic Intelligence Tübingen Stuttgart (BITS) collaboration developed a biorobotic arm that can mirror human tremors. Artificial muscles on either side of the forearm contract and relax to suppress the involuntary shaking of the wrist and hand.

This year, the Brain Prize worth more than one million euros, honors pioneering work on nervous system-cancer interactions: Neurologist Frank Winkler, who researches at the Heidelberg University and at the German Cancer Research Center and treats patients with brain tumors at the Heidelberg University Hospital, discovered that nerve cells in the brain communicate with brain tumor cells. This causes the disease to progress.

Targeted molecular interventions in the replication cycle and the immune recognition of viruses are intended to prevent viral entry into cells and virus replication. Scientists work on new approaches to combating highly dangerous viral diseases such as yellow fever or Lassa fever. The European Union is supporting the project over a period of five years to the tune of just under eight million euros.

Researchers of the Heidelberg University, Heidelberg University Hospital (UKHD) and Heidelberg Institute for Theoretical Studies (HITS) have developed a synthetic peptide based on the natural protein S100A1, a nearly universal “fuel” for weakened hearts. The researchers combined computer-aided methods with lab studies to investigate the therapeutic effect of the so called S100A1ct peptide molecule.

Scientists from the German Cancer Research Center (DKFZ) and ShanghaiTech University have developed an innovative method for growing brain tumors of individual patients in the laboratory that mimic the original structure and the molecular property of the parental tumor as closely as possible. Drug tests in this model were found to correlate very well with actual patient responses, making it a valuable method for investigating therapies.

In collaboration with Heraeus, the German Institutes of Textile and Fiber Research (DITF) are developing fibers and textiles with a novel infection protection system. The basis is an antimicrobial mechanism of action licensed from Heraeus and marketed under the name AGXX. The goal of the collaboration is to optimally integrate the AGXX technology into textile finishes and coatings and to incorporate it into fiber-spinnable polymers.

The spliceosome, ensures that the genetic information from the genome, after being transcribed into mRNA precursors, is correctly assembled into mature mRNA. Splicing is a basic requirement for producing proteins. Researchers at the Heidelberg University Biochemistry Center (BZH) have succeeded for the first time in depicting a faultily “blocked” spliceosome at high resolution and reconstructing how it is recognized and eliminated in the cell.

A research team from the Heidelberg Medical Faculty, the German Cancer Research Center, the Berlin Institute of Health at Charité (BIH) and the Max Delbrück Center has discovered new details about the spread of the incurable bone marrow cancer multiple myeloma in the body: When the cancer cells break out of the bone and multiply outside the bone marrow, a wide variety of tumor cells arise, accompanied by a significantly altered immune response.

Konstanz biologist Patrick Müller receives a Proof of Concept Grant from the European Research Council for his project "EmbryoNet-AI". Its goal is the further development of an AI-supported platform for the automated evaluation of experiments – for example, in drug development.

Young patients suffering from two aggressive sarcoma types can now participate in the innovative PAMSARC therapy study at the NCT Heidelberg. The study uses molecular biological methods and tests the extent to which a new drug can improve the poor prognosis for these tumours.

Dr. Petr Chlanda, virologist and research group leader at the Heidelberg Medical Faculty of Heidelberg University, has been awarded more than 720,000 euros in funding from the European Union for his research into new therapies against viruses. His work is part of the interdisciplinary, international DEFENDER project, which is developing innovative approaches to combat emerging and re-emerging viruses.

The MedTech company KARL STORZ announces the acquisition of the innovative software manufacturer Innersight Labs Ltd. (ISL) headquartered in London. In addition to state-of-the-art endoscopes, high-end medical devices, and integrated solutions for the operating room, KARL STORZ is also continuing to expand in innovative software solutions. Its large customer base, including top-class physicians worldwide, can now look forward to 3D models.

Tumor cells circulating in the blood are the "germ cells" of breast cancer metastases. They are rare and could not be propagated in the culture dish until now, which made research into therapy resistance difficult. A team from the DKFZ, the Heidelberg Stem Cell Institute HI-STEM and the NCT Heidelberg has now succeeded for the first time in cultivating stable tumor organoids directly from blood samples of breast cancer patients.

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December 2024.

Up to now, schizophrenia has mainly been treated symptomatically, as little is known about the exact underlying processes. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen have succeeded in gaining a better understanding of the driving mechanisms of the disease. This offers opportunities for the development of new drugs. They have published their findings in the journal BMC Psychiatry.

Researchers at the Medical Faculty of Heidelberg University and the Heidelberg University Hospital have used modified rabies viruses to label glioblastoma tumour cells and their direct cell contacts in the mouse brain. The new method showed that the tumour cells are connected to different types of nerve cells throughout the entire brain at a very early stage of the disease.

Dossier: Innovative animal-free research in Baden-Württemberg - 05/12/2024

Mini-organs and multi-organ chips - where lab mice may soon retire

Farewell to animal testing? Life sciences researchers in BW are pioneering innovative methods to replace animal experiments, reduce the number of animals used and refine the procedures and conditions under which animals are kept. These are the guiding principles of the 3Rs principle. Developing cutting-edge models and establishing a robust 3R network, not only shapes the future of research but also improves the quality of scientific outcomes.

The NMI Natural and Medical Sciences Institute and the Karlsruhe Institute of Technology (KIT) have signed a groundbreaking cooperation agreement. This partnership combines the expertise of both institutions in the fields of production and characterization of materials for biological systems and energy storage as well as the application of statistical methods in medicine.

Vicinity Bio: Optimisation of cancer diagnostics - 27/11/2024

Comprehensive histological diagnostics through high-dimensional imaging and artificial intelligence

Microscopic examination of tissue samples is essential, particularly in tumour diagnostics. The Tübingen-based company Vicinity Bio leverages cutting-edge imaging technologies combined with machine learning to generate comprehensive datasets of individual cells from tissue sections. This approach not only helps identify more targeted therapies but also enhances our understanding of cellular functions and processes within tissues and tumours.